Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy

Stage III non-small-cell lung cancer (NSCLC) with N2 lymph node involvement is a heterogeneous group with different potential therapeutic approaches. Patients with potentially resectable III-N2 NSCLC are those who are considered to be able to receive a multimodality treatment that includes tumour re...

Full description

Bibliographic Details
Main Authors: Xabier Mielgo-Rubio, Sara Montemuiño, Unai Jiménez, Javier Luna, Ana Cardeña, Laura Mezquita, Margarita Martín, Felipe Couñago
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
non-small-cell lung cancer
NSCLC
N2
resectable
immunotherapy
stage III
Online Access:https://www.mdpi.com/2072-6694/13/19/4811

Internet

https://www.mdpi.com/2072-6694/13/19/4811

Similar Items